We show readers that GLP-1RAs have also been found to significantly reduce the risks of heart failure, atherosclerosis (AS), and hypertension, highlighting their broad therapeutic potential
AstraZeneca stated that it views its oral GLP-1 elecoglipron as the foundation of a broader obesity strategy, potentially including combinations with its medicines for type 2 diabetes and kidney and heart disease
Individual results are not typical and may vary
Add them to yogurt for a sweet, fiber-packed snack
Retatrutide's triple-receptor mechanism means its full safety profile is still being characterised through ongoing clinical trials, and vigilance is particularly important during this period
Animal and clinical studies have shown that GLP-1RAs ameliorate liver inflammation and lower the risk of NAFLD and NASH developing into liver cancer